Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
{{output}}
Background & aims: In the phase III HIMALAYA study (NCT03298451), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib in unresectable HCC (uHCC) and demonstrated ... ...
